BELLEROPHON THERAPEUTICS INC's ticker is BLPH and the CUSIP is 078771102. A total of 15 filers reported holding BELLEROPHON THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $587,000 | -21.8% | 1,679,303 | +7.8% | 0.00% | -100.0% |
| Q3 2019 | $751,000 | -12.7% | 1,557,803 | +8.6% | 0.00% | 0.0% |
| Q2 2019 | $860,000 | 0.0% | 1,434,538 | +8.9% | 0.00% | 0.0% |
| Q1 2019 | $860,000 | -14.5% | 1,317,676 | +5.0% | 0.00% | 0.0% |
| Q4 2018 | $1,006,000 | -23.2% | 1,255,476 | +3.5% | 0.00% | 0.0% |
| Q3 2018 | $1,310,000 | -73.6% | 1,213,276 | -44.7% | 0.00% | -66.7% |
| Q2 2018 | $4,953,000 | +130.6% | 2,192,100 | +112.2% | 0.00% | +50.0% |
| Q1 2018 | $2,148,000 | -10.2% | 1,032,900 | +11.4% | 0.00% | -33.3% |
| Q4 2017 | $2,392,000 | +127.6% | 927,200 | +25.3% | 0.00% | +200.0% |
| Q3 2017 | $1,051,000 | +26.8% | 740,000 | +19.7% | 0.00% | 0.0% |
| Q2 2017 | $829,000 | +16.6% | 618,300 | +29.5% | 0.00% | 0.0% |
| Q1 2017 | $711,000 | +473.4% | 477,400 | +99.7% | 0.00% | – |
| Q4 2016 | $124,000 | +59.0% | 239,100 | +330.8% | 0.00% | – |
| Q3 2016 | $78,000 | +110.8% | 55,500 | +168.1% | 0.00% | – |
| Q2 2016 | $37,000 | – | 20,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 1,857,143 | $966,000 | 0.37% |
| NEW MOUNTAIN VANTAGE ADVISERS, L.L.C. | 10,574,171 | $5,499,000 | 0.35% |
| ARMISTICE CAPITAL, LLC | 1,000,000 | $520,000 | 0.12% |
| SABBY MANAGEMENT, LLC | 789,857 | $414,000 | 0.02% |
| Alyeska Investment Group, L.P. | 154,290 | $80,000 | 0.00% |
| Geneva Advisors, LLC | 12,500 | $7,000 | 0.00% |
| MORGAN STANLEY | 1,000 | $0 | 0.00% |
| LPL Financial LLC | 95,035 | $51,000 | 0.00% |
| Citadel Advisors | 28,120 | $15,000 | 0.00% |
| Renaissance Technologies | 239,100 | $124,000 | 0.00% |